• Different treatment options have been introduced and evaluated from a health economic perspective. However, given the specific characteristics of the disease an evaluation of existing models is needed.
METHODS:
• The following databases were searched systematically: PubMed, Health Technology Assessment Database, NHS Economic Evaluation Database, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, DAHTA-database, PSYNDEX and PsycINFO.
• For the abstracts that met the pre-defined inclusion criteria, full text articles were obtained and evaluated for inclusion in the assessment. 
RESULTS:
• After eliminating duplicates the search yielded 1'219 articles of which another 940 were excluded based on the title selection. Finally 59 articles have been reviewed in full text after abstract review. Out of those articles 41 were deemed to be relevant based on the research question.
• The vast majority of models (80%) have been Markov models, other methods being used were various statistical analysis applications, micro-simulation, and discrete-event simulations.
• Only a small number of analyses was developed to find the cost-effectiveness between the active treatments:
-Bond 2012 analyzed all AChEIs and memantine vs each other in the UK (Markov model).
-Hyde 2013 validated the findings by Bond 2012 in developing a cohort-based model and also comparing all AChEIs and memantine vs each other.
-Touchon 2013 analysed all AChEIs and memantine vs each other in France.
• The other 38 analyses compared active treatments versus placebo (one model could also analyse different treatments):
-22 models compared Donepezil versus placebo.
-19 models compared memantine versus placebo.
-11 models compared galantamine versus placebo.
-7 models compared rivastigmine versus placebo.
• Even though that there is discussion on the usefulness and interpretability of the QALY concept in a diseases such as Alzheimer's Disease, 24 models had the Cost per QALY as a health economic endpoint (57%).
-Further health economic endpoints were reporting on total costs in contrast to the clinical outcome measurement used in the respective model (n = 14 models; 33%).
-Cost-effectiveness was also only used twice and cost comparison only once.
• The clinical endpoints utilized in the models can generally be split between the measurement of severity of the disease which was mostly included using the MMSE scores and the time until institutionalization. Institutionalization can be further broken down in time until nursing home, full-time and part-time institutionalization:
-Severity was used as a clinical endpoint in 23 studies (54%)
-Institutionalization was included in 15 models (36%)
-ADCS-ADL or other ADL measures were used in 7 models (17%)
-Other measures (e.g. CDR, SIB) were used as a clinical endpoint in 6 models (14%)
DISCUSSIONS:
• Limitations of existing models include the following:
-Focus on cognitive function as disease progression only.
 As seen above most models only utilized the MMSE score as a standard clinical measure for disease progression. However, clinical research has shown that other factors such as ability to speak and eat for example might also have a significant impact in patient's and caregiver's life. These measure could have had an important influence on the utilities calculated in the models. Additionally, some therapies have only shown a clinical benefit in the MMSE score but no benefit when other measures were being used (see Walzer et al. Value in Health 2014).
-Lack of inclusion of correlation between disease progression and other factors (e.g. residential status).
 Even though that some models used institutionalization as a primary clinical endpoint it was only used in Fagnani 2003 and Neumann 1999 together with a severity scale. Most other models did not directly use the correlation between the disease progression (not only on a cognitive level) and residential status. Furthermore the severity of the disease might have an impact on the caregiver's life (see below).
-Lack of complete structure of diagnosis and treatment of disease (e.g. including non-drug treatments).
 All models lack a complete structure of the disease. Normally the focus is only on drug treatment and also excludes non-drug treatments and support of the patient and caregivers. However, diagnostic and other treatment factors might have an important impact on the overall health economic result, especially in case the disease progression might has been delayed and the severity of the disease could have had an impact on non-drug therapies or caregiver's freedom and utilities.
-Lack of inclusion of caregiver cost and utilities.
 The utilities from a societal perspective are not taken into account in any model. Even though that there are factors which impact cost and utilities of caregivers:
Cost: e.g. potential reduction in working hours.
Utilities: Disutilities in terms of social stress, lack of freedom, etc.
 It seems caregivers themselves systematically underestimate the impact of caring for an AD patient on their own time. However informal care itself is a recurrent factor and needs consideration beside QoL:
Many caregivers report devoting up to 24 hours a day to supervising activities, and this impacts their own time, their families, their QoL and has severe financial implications (Gage et al. 2014 ).
-As most pricing and reimbursement agencies request it, the choice of Cost per QALY as the predominant health economic endpoint was chosen, even though…  Patients consistently report a better quality of life (QoL) to others (e.g. caring relatives and caregivers) (Moyle et al. 2011) , until patients are no longer able to self-report QoL. Potentially this is the case because AD doesn't normally cause pain or major impairment. This fact might especially also hold true for the EQ-5D as being the standard to measure utilities.
 At the same time, because it is such a unique condition and affects so many different aspects of life, AD is difficult to fully capture. Accordingly, the adequate selection of outcome measures (e.g. cost per time to institutionalization) will largely depends on the modeling scope and goal. A cost-consequences analysis with non-aggregated outcome measures may be a valid option, rather than trying to express everything as a "cost per something" -in fact 15 identified studies (35%) used such a format in their models.
-Finally, 39 out of 42 models analyzed an active treatment versus placebo which is not decision maker relevant, especially not in cases where an active treatment is available. Indirect comparison and mixed-treatment comparisons could have been utilized in order to compare different active therapies against each other. Furthermore there are a couple of head-to-head clinical trials available which could have also been used as a basis for those models.
CONCLUSIONS:
• Current models do not allow decision makers optimally characterizing the disease, to better assess the costs and benefits of a wide range of potential interventions.
• Potential new models need to take the disease characteristics and specifics more appropriate into account.
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